ZECH, M., S. BOESCH, M. SKORVANEK, J. NECPAL, J. SVANTNEROVA, M. WAGNER, Y. DINCER, A. SADR-NABAVI, T. SERRANOVA, Irena REKTOROVÁ, P. HAVRANKOVA, S. GANAI, A. MOSEJOVA, I. PRIHODOVA, J. SARLAKOVA, K. KULCSAROVA, O. ULMANOVA, K. BECHYNE, M. OSTROZOVICOVA, V. HAN, J. R. VENTOSA, M. SHARIATI, A. SHOEIBI, S. WEBER, B. MOLLENHAUER, C. TRENKWALDER, R. BERUTTI, T. M. STROM, A. CEBALLOS-BAUMANN, V. MALL, B. HASLINGER, R. JECH and J. WINKELMANN. Clinically relevant copy-number variants in exome sequencing data of patients with dystonia. PARKINSONISM & RELATED DISORDERS. OXFORD: ELSEVIER SCI LTD, 2021, vol. 84, MAR 2021, p. 129-134. ISSN 1353-8020. Available from: https://dx.doi.org/10.1016/j.parkreldis.2021.02.013.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinically relevant copy-number variants in exome sequencing data of patients with dystonia
Authors ZECH, M. (guarantor), S. BOESCH, M. SKORVANEK, J. NECPAL, J. SVANTNEROVA, M. WAGNER, Y. DINCER, A. SADR-NABAVI, T. SERRANOVA, Irena REKTOROVÁ (203 Czech Republic, belonging to the institution), P. HAVRANKOVA (203 Czech Republic), S. GANAI, A. MOSEJOVA, I. PRIHODOVA (203 Czech Republic), J. SARLAKOVA (203 Czech Republic), K. KULCSAROVA, O. ULMANOVA (203 Czech Republic), K. BECHYNE, M. OSTROZOVICOVA, V. HAN, J. R. VENTOSA, M. SHARIATI, A. SHOEIBI, S. WEBER, B. MOLLENHAUER, C. TRENKWALDER, R. BERUTTI, T. M. STROM, A. CEBALLOS-BAUMANN, V. MALL, B. HASLINGER, R. JECH (203 Czech Republic) and J. WINKELMANN.
Edition PARKINSONISM & RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2021, 1353-8020.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.402
RIV identification code RIV/00216224:14110/21:00121363
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.parkreldis.2021.02.013
UT WoS 000628766400001
Keywords in English Copy-number variant; Dystonia; Read-depth analysis; Diagnostic yield
Tags 14110127, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 18/1/2022 09:40.
Abstract
Introduction: Next-generation sequencing is now used on a routine basis for molecular testing but studies on copy-number variant (CNV) detection from next-generation sequencing data are underrepresented. Utilizing an existing whole-exome sequencing (WES) dataset, we sought to investigate the contribution of rare CNVs to the genetic causality of dystonia. Methods: The CNV read-depth analysis tool ExomeDepth was applied to the exome sequences of 953 unrelated patients with dystonia (600 with isolated dystonia and 353 with combined dystonia; 33% with additional neurological involvement). We prioritized rare CNVs that affected known disease genes and/or were known to be associated with defined microdeletion/microduplication syndromes. Pathogenicity assessment of CNVs was based on recently published standards of the American College of Medical Genetics and Genomics and the Clinical Genome Resource. Results: We identified pathogenic or likely pathogenic CNVs in 14 of 953 patients (1.5%). Of the 14 different CNVs, 12 were deletions and 2 were duplications, ranging in predicted size from 124bp to 17 Mb. Within the deletion intervals, BRPF1, CHD8, DJ1, EFTUD2, FGF14, GCH1, PANK2, SGCE, UBE3A, VPS16, WARS2, and WDR45 were determined as the most clinically relevant genes. The duplications involved chromosomal regions 6q21-q22 and 15q11-q13. CNV analysis increased the diagnostic yield in the total cohort from 18.4% to 19.8%, as compared to the assessment of single-nucleotide variants and small insertions and deletions alone. Conclusions: WES-based CNV analysis in dystonia is feasible, increases the diagnostic yield, and should be combined with the assessment of single-nucleotide variants and small insertions and deletions.
Links
825575, interní kód MUName: European Joint Programme on Rare Diseases (Acronym: EJP RD)
Investor: European Union, Health, demographic change and wellbeing (Societal Challenges)
PrintDisplayed: 15/7/2024 01:32